The stock of Actinium Pharmaceuticals Inc (NYSEAMERICAN:ATNM) closed at $0.674 losing 4.18% in yesterday’s trading session. Actinium has moved ahead to post positive DMC View on Iomab-B (apamistamab) and of course that was on its Phase III trial that was conducted recently.
The Company’s lead pipeline candidate will play a huge role in terms of conditioning patients before they move ahead to undertake a bone marrow transplant (BMT) with refractory or relapsed acute myeloid leukemia (AML) aged 55 years and beyond.
If everything goes according to plan, it is expected that the phase III study will be enrolling about 150 patients.
The company’s spokesperson opined, “The trial is evaluating the candidate in comparison to chemotherapy as per physician’s choice on AML patients followed by a BMT, also referred to as a hematopoietic stem cell transplant. While the primary endpoint of the study is durable Complete Remission (dCR) at six months post treatment, the secondary endpoint is overall survival at one year.”
On top of that, the Company proceeded to disclose that it had plans underway to make a request of some two ad-hoc efficacy analyses after 70 and/or 110 patients receive the treatment. There will be great need to give the patients sufficient time so that they will be able to reach the primary endpoint.
Back in November, DMC conducted an in-depth review of the initial safety data emanating from the first 20 patients that had enrolled in the trial. The DMC is set to move further with the enrollment for the research. Actinium has also stated that it is on course towards reaching its set target. The trail might be completed by the end of 2018 and that will be in line with a prior forecast.
It is also critical to point out that this company is currently on course towards achieving immense success with its phase III study in seven other sites, Canada being one of them. Back in May, the company was cleared to move ahead with its plan to initiate the study from Health Canada. The company is reminding all its investors that the Iomab-B was granted with an Orphan Drug Designation by the European Medicines Agency and FDA in line with the aforementioned indication.